Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Rapid Infusion Daratumumab Is Safe in Patients with AL Amyloidosis

Nathaniel Rosko, PharmD, Hanjie Mo, PharmD, Joslyn Rudoni, PharmD, Caitlin Siebenaller, PharmD, Sarah S Lee, MD, Rajshekar Chakraborty, MD, Beth M. Faiman, PhDCNP, Jack Khouri, MD, Alex V. Mejia Garcia, MD, Christy J. Samaras, DO, Faiz Anwer, MD, Jason Valent, MD

Blood (2019) 134 (Supplement_1): 1838.

https://doi.org/10.1182/blood-2019-124775

Published: 2019

Journal Articles

Population Pharmacokinetics of Ivosidenib (AG-120) in Patients with IDH1-Mutant Advanced Hematologic Malignancies

Kha Le, PhD, Russ Wada, PhD, David Dai, PhD, Bin Fan, PhD, Guowen Liu, PhD, Hua Liu, PhD, Eyal C. Attar, MD, Samuel V. Agresta, MD, Hua Yang, PhD

Blood (2018) 132 (Supplement 1): 1394.

https://doi.org/10.1182/blood-2018-99-109863

Published: 2018

Journal Articles

Safety, Tolerability and Response Rates of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Results of a Phase II Study

Vaishali Sanchorawala, MD, Shayna Sarosiek, MD, John Mark Sloan, MD, Dina Brauneis, NP, Mary Ellen Migre, Meredith Mistark, Stephanie Santos, Ramon Cruz, Salli Fennessey, Anthony C Shelton, RN

Blood (2018) 132 (Supplement 1): 2005.

https://doi.org/10.1182/blood-2018-99-112991

Published: 2018

Journal Articles

Safety and Tolerability of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Preliminary Results of a Phase II Study

Vaishali Sanchorawala, MD, Shayna Sarosiek, MD, John Mark Sloan, MD, Dina Brauneis, NP, Mary Ellen Migre, Meredith Mistark, Stephanie Santos, Salli Fennessey, Anthony C Shelton, RN

Blood (2017) 130 (Supplement 1): 507.

https://doi.org/10.1182/blood.V130.Suppl_1.507.507

Published: 2017

Journal Articles

Drug-Induced Immune Thrombocytopenia (DITP) Caused By Multiple Drug-Dependent Platelet-Reactive Antibodies (DDAbs) in Patients Undergoing Oxaliplatin-Containing Combination Chemotherapy for Metastatic Colon Cancer

Brian R. Curtis, PhDMT(ASCP), Yen-Michael S. Hsu, MD PhD, Nikolai A. Podoltsev, MD PhD, Jill Lacy, MD, Susanna A Curtis, MD, Robert Andrew Desimone, MD, Michael Samuel, MD, Kristin Zutavern, BS, Daniel Bougie, PhD, Richard H. Aster, MD

Blood (2017) 130 (Supplement 1): 3625.

https://doi.org/10.1182/blood.V130.Suppl_1.3625.3625

Published: 2017

Journal Articles

Monoclonal Antibody Utilization Characteritics in Patients with Multiple Myeloma

Sikander Ailawadhi, Abdel-Ghani Azzouqa, Zahara Meghji, Tania Jain, MD, Nancy Diehl, Stephanie P. Gebhardt, Vishal Shah, David O. Hodge, MS, Raj Patel, MD, Prachi Jani, MD, Taimur Sher, MD, Vivek Roy, MD, Meghna Ailawadhi, MD, Victoria R. Alegria, Aneel Paulus, MD, Asher A. Chanan-Khan, MD, Rafael Fonseca, MD

Blood (2017) 130 (Supplement 1): 5440.

https://doi.org/10.1182/blood.V130.Suppl_1.5440.5440

Published: 2017

Journal Articles

Phase Ib Study of Isatuximab and Carfilzomib in Relapse and Refractory Multiple Myeloma

Thomas G. Martin, III, MD, Gabriel N Mannis, Ajai Chari, MD, Pamela Munster, MD, Frank Campana, MD, Ai-Min Hui, MD PhD, Jeffrey L. Wolf, MD

Blood (2016) 128 (22): 2111.

https://doi.org/10.1182/blood.V128.22.2111.2111

Published: 2016

Journal Articles

Phase II Trial Daily Pulse Interleukin-2 Therapy with Famotidine during Marrow and Lymphocyte Recovery in Acute Myeloid Leukemia: LJCC 0605

Reed Friend, MD, Ridas Juskevicius, MD, Lauren Salmon, DO, Hemant S. Murthy, MD, James Xenakis, Adam S. Asch, MD, Paul Walker, MD

Blood (2015) 126 (23): 3783.

https://doi.org/10.1182/blood.V126.23.3783.3783

Published: 2015

Journal Articles

Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach For Proteasome-Inhibitor Based Therapy In Waldenstrom’s Macroglobulinemia

Steven Peter Treon, MD, MA, PhD, Christina K Tripsas, MA, Kirsten Meid, MPH, Steven J Cropper, Patrick Mostyn, Diane Warren, Claudia E. Paba-Prada, MD, Christopher Patterson, Guang Yang, PhD, Zachary Hunter, Janet Kunsman, NP, Sandra Kanan, NP, Irene M. Ghobrial, MD

Blood (2013) 122 (21): 757.

https://doi.org/10.1182/blood.V122.21.757.757

Published: 2013

Journal Articles

Results of A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma,

Beth Christian, MD, Lapo Alinari, MD., Ph.D., Jeffrey A. Jones, MD, MPH, Don M Benson, Jr., MD, PhD, Joseph M. Flynn, DO, MPH, Pierluigi Porcu, MD, Mark E Lustberg, MD, PhD, Mitchell Phelps, Ph.D., Ming Poi, PharmD, PhD, Diana Chung, BS, Carl Quinion, John C. Byrd, MD, William Wegener, MD, PhD, David M Goldenberg, Robert A. Baiocchi, M.D., Ph.D., Kristie A. Blum, MD

Blood (2011) 118 (21): 3707.

https://doi.org/10.1182/blood.V118.21.3707.3707

Published: 2011

Journal Articles

Dasatinib (Versus Imatinib) In Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of Safety and Efficacy by Use of Baseline Medications In the DASISION Trial

Francois Guilhot, Hagop Kantarjian, MD, Neil P. Shah, Andreas Hochhaus, M. Brigid Bradley-Garelik, David Dejardin, Jorge E. Cortes, MD

Blood (2010) 116 (21): 2295.

https://doi.org/10.1182/blood.V116.21.2295.2295

Published: 2010

Journal Articles

A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma.

Beth Christian, MD, Lapo Alinari, MD, Christian Tyler Earl, Emily Wilding, Carl Quinion, Mark Lustberg, MD, PhD, Don M Benson, Jr., MD, PhD, Jeffrey A. Jones, MD, MPH, John C. Byrd, MD, William A. Wegener, MD, PhD, David M. Goldenberg, ScD, MD, Robert A. Baiocchi, MD, PhD, Kristie A. Blum, MD

Blood (2010) 116 (21): 2788.

https://doi.org/10.1182/blood.V116.21.2788.2788

Published: 2010

Journal Articles

Piperacillin Induced Thrombocytopenia in Critical Care Patients as Compared to Non Critical Patients.

Seema Naik, MD, Ashish Sangal, MD, Srinivas Kodali, MD, Theresa Dumlao, MD, Madhumati Kalavar, MD, William Steier, MD, Zili He

Blood (2007) 110 (11): 3916.

https://doi.org/10.1182/blood.V110.11.3916.3916

Published: 2007

NARROW

Rapid Infusion Daratumumab Is Safe in Patients with AL Amyloidosis

Population Pharmacokinetics of Ivosidenib (AG-120) in Patients with IDH1-Mutant Advanced Hematologic Malignancies

Safety, Tolerability and Response Rates of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Results of a Phase II Study

Safety and Tolerability of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Preliminary Results of a Phase II Study

Drug-Induced Immune Thrombocytopenia (DITP) Caused By Multiple Drug-Dependent Platelet-Reactive Antibodies (DDAbs) in Patients Undergoing Oxaliplatin-Containing Combination Chemotherapy for Metastatic Colon Cancer

Monoclonal Antibody Utilization Characteritics in Patients with Multiple Myeloma

Phase Ib Study of Isatuximab and Carfilzomib in Relapse and Refractory Multiple Myeloma

Phase II Trial Daily Pulse Interleukin-2 Therapy with Famotidine during Marrow and Lymphocyte Recovery in Acute Myeloid Leukemia: LJCC 0605

Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach For Proteasome-Inhibitor Based Therapy In Waldenstrom’s Macroglobulinemia

Results of A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma,

Dasatinib (Versus Imatinib) In Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of Safety and Efficacy by Use of Baseline Medications In the DASISION Trial

A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma.

Piperacillin Induced Thrombocytopenia in Critical Care Patients as Compared to Non Critical Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only